Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 88 | 4,519 | 46% |
| 2020 | 66 | 3,805 | 48% |
| 2021 | 74 | 4,379 | 51% |
| 2022 | 74 | 4,690 | 53% |
| 2023 | 75 | 4,770 | 55% |
| 2024 | 82 | 4,973 | 57% |
| 2025 from claims | – | 5,790 5,313–6,126 | 58% |
| 2026 forecast | – | 6,090 5,358–7,027 | 58% |
| 2027 forecast | – | 6,377 5,452–7,600 | 59% |
| 2028 forecast | – | 6,678 5,572–8,177 | 59% |
| 2029 forecast | – | 6,991 5,710–8,767 | 60% |
| 2030 forecast | – | 7,318 5,862–9,377 | 60% |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 36% of the cases CMS names in New York; 41 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 22% inpatient hospital, 78% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~6,100 | ~1,300 | ~4,800 |
| 2027 · ~6,400 | ~1,300 | ~5,100 |
| 2028 · ~6,700 | ~1,400 | ~5,300 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 20% (22% in 2025), hospital outpatient about 80% (78% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 75 | 5,343+1.2%/yr | +1.2%/yr | 4.0 | 0% | 7,380 in 2030+5.5%/yr |
| Massachusetts | 48 | 3,057+5.5%/yr | +5.5%/yr | 3.3 | 0% | 4,980 in 2030+8.5%/yr |
| New Jersey | 36 | 2,104+9.9%/yr | +9.9%/yr | 2.0 | 0% | 4,020 in 2030+11%/yr |
| Connecticut | 12 | 1,083+3.5%/yr | +3.5%/yr | 3.3 | 0% | 2,100 in 2030+12%/yr |
| New Hampshire | 8 | 422+0.3%/yr | +0.3%/yr | 1.9 | 0% | 790 in 2030+11%/yr |
| Maine | 3 | 224−7.6%/yr | −7.6%/yr | 1.4 | 0% | 320 in 2030+6.4%/yr |
| Vermont | 4 | 192+6.8%/yr | +6.8%/yr | 1.7 | 0% | 560 in 2030+20%/yr |
| Rhode Island | 4 | 147+4.9%/yr | +4.9%/yr | 1.6 | 0% | 310 in 2030+13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 1,378 | 235,327−1.7%/yr | −1.7%/yr | 134.51.1× | 54% | 246,900 in 2030+0.8%/yr |
| ERCP & endoscopic ultrasound | 101 | 6,049−4.1%/yr | −4.1%/yr | 3.40.9× | 1% | 6,420 in 2030+1%/yr |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
Capsovision leads with 35% of company spending on these surgeons in 2025, +27 pts on 2024.
In 2025, 24 companies reported engagement with New York’s surgeons worth $434K in consulting, speaking, meals and travel tied to these products, about $5,287 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.